stockrowVeracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
- Revenue
- +15.1%
- EPS
- +62.5%
- Free cash flow
- −9.63%
Quarter to September 2026, against a year earlier
Follow VCYT
Alert me
Veracyte, Inc. (VCYT) Revenue
Veracyte, Inc.'s revenue for fiscal 2025 was $517.1M, up 16.0% from $445.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was $581.8M. Over the past ten years it has ranged from $49.5M (fiscal 2015) to $517.1M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 5 consecutive fiscal years. Veracyte, Inc. ranks 22nd of 47 Diagnostics & Research companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $517.1M | 16.01% |
| FY2024 | $445.8M | 23.46% |
| FY2023 | $361.1M | 21.76% |
| FY2022 | $296.5M | 35.09% |
| FY2021 | $219.5M | 86.85% |
| FY2020 | $117.5M | (2.40%) |
| FY2019 | $120.4M | 30.82% |
| FY2018 | $92.0M | 27.87% |
| FY2017 | $72.0M | 10.55% |
| FY2016 | $65.1M | 31.48% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $151.8M | 0.95% |
| Jun 2026 | $150.3M | 8.09% |
| Mar 2026 | $139.1M | (1.11%) |
| Dec 2025 | $140.6M | 6.65% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| RDNT RadNet, Inc. compare | $2.3B |
| SHC Sotera Health Company compare | $1.2B |
| NEO NeoGenomics, Inc. compare | $787.8M |
| VCYT Veracyte, Inc. | $581.8M |
| CDNA CareDx, Inc. compare | $497.4M |
| WGS GeneDx Holdings Corp. compare | $454.4M |
| BLLN BillionToOne, Inc. compare | $436.9M |
| ADPT Adaptive Biotechnologies Corporation compare | $298.0M |
| GRAL GRAIL, Inc. compare | $166.6M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on VCYT
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement